The Inhibitory Role of MiR-486-5p on CSC Phenotype Has Diagnostic and Prognostic Potential in Colorectal Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Nov 24

PMID 33227890

Citations 16

Authors

Andrea Pisano

Carmen Grinan-Lison

Cristiano Farace

Giovanni Fiorito

Grazia Fenu

Gema Jimenez

Fabrizio Scognamillo

Jesus Pena-Martin

Alessio Naccarati

Johannes Proll

Sabine Atzmuller

Barbara Pardini

Federico Attene

Gabriele Ibba

Maria Giuliana Solinas

David Bernhard

Juan Antonio Marchal

Roberto Madeddu

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is the third most frequent cancer worldwide and the second cause of cancer deaths. Increasing evidences supports the idea that the poor prognosis of patients is related to the presence of cancer stem cells (CSCs), a cell population able to drive cancer recurrence and metastasis. The deregulation of microRNAs (miRNAs) plays a role in the formation of CSC. We investigated the role of hsa-miR-486-5p (miR-486-5p) in CRC, CSCs, and metastasis, in order to reach a better understanding of the biomolecular and epigenetic mechanisms mir-486-5p-related. The expression of miR-486-5p was investigated in three different matrices from CRC patients and controls and in CSCs obtained from the CRC cell lines HCT-116, HT-29, and T-84. In the human study, miR-486-5p was up-regulated in serum and stool of CRC patients in comparison with healthy controls but down-regulated in tumor tissue when compared with normal mucosa. miR-486-5p was also down-regulated in the sera of metastatic patients. In vitro, miR-486-5p was down-regulated in CSC models and it induced an inhibitory effect on stem factors and oncogenes in the main pathways of CSCs. Our results provide a step forward in understanding the role of mir-486-5p in CRC and CSC, and suggest that further studies are needed to investigate its diagnostic and prognostic power, possibly in combination with other biomarkers.

Citing Articles

Detection of Cancer Stem Cells from Patient Samples.

Hakala S, Hamalainen A, Sandelin S, Giannareas N, Narva E Cells. 2025; 14(2).

PMID: 39851576 PMC: 11764358. DOI: 10.3390/cells14020148.

The Role of miR-486-5p on CSCs Phenotypes in Colorectal Cancer.

Etzi F, Grinan-Lison C, Fenu G, Gonzalez-Titos A, Pisano A, Farace C Cancers (Basel). 2025; 16(24.

PMID: 39766136 PMC: 11674241. DOI: 10.3390/cancers16244237.

Bioinformatics and assays identified miR-486-5p as a tumor suppressor miRNA in hepatocellular carcinoma.

Li X, Fang J, Huang X, Wu Y, Wang R Heliyon. 2025; 10(24):e39909.

PMID: 39759296 PMC: 11700245. DOI: 10.1016/j.heliyon.2024.e39909.

Therapeutic Potential of Feline Adipose-Derived Stem Cell Exosomes in the Treatment of Feline Idiopathic Cystitis: A Characterization and Functional Analysis of miRNA Content.

Rubini A, Zanotti F, Licastro D, Calogero G, Bettini G, Piccoli C Nanotheranostics. 2025; 9(1):38-51.

PMID: 39744099 PMC: 11667565. DOI: 10.7150/ntno.99383.

Mesenchymal stem cell-derived exosomes carrying miR-486-5p inhibit glycolysis and cell stemness in colorectal cancer by targeting NEK2.

Cui F, Chen Y, Wu X, Zhao W BMC Cancer. 2024; 24(1):1356.

PMID: 39506654 PMC: 11539302. DOI: 10.1186/s12885-024-13086-9.

References

Ibrahim E, Babaei-Jadidi R, Saadeddin A, Spencer-Dene B, Hossaini S, Abuzinadah M . Embryonic NANOG activity defines colorectal cancer stem cells and modulates through AP1- and TCF-dependent mechanisms. Stem Cells. 2012; 30(10):2076-87. DOI: 10.1002/stem.1182. View

Suh E, Traber P . An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cell Biol. 1996; 16(2):619-25. PMC: 231041. DOI: 10.1128/MCB.16.2.619. View

Ferrero G, Cordero F, Tarallo S, Arigoni M, Riccardo F, Gallo G . Small non-coding RNA profiling in human biofluids and surrogate tissues from healthy individuals: description of the diverse and most represented species. Oncotarget. 2018; 9(3):3097-3111. PMC: 5790449. DOI: 10.18632/oncotarget.23203. View

Barr F, Sillje H, Nigg E . Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol. 2004; 5(6):429-40. DOI: 10.1038/nrm1401. View

Barrett T, Wilhite S, Ledoux P, Evangelista C, Kim I, Tomashevsky M . NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2012; 41(Database issue):D991-5. PMC: 3531084. DOI: 10.1093/nar/gks1193. View

Miyaki M, Iijima T, Konishi M, Sakai K, Ishii A, Yasuno M . Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene. 1999; 18(20):3098-103. DOI: 10.1038/sj.onc.1202642. View

Xiao L, Yuan X, Sharkis S . Activin A maintains self-renewal and regulates fibroblast growth factor, Wnt, and bone morphogenic protein pathways in human embryonic stem cells. Stem Cells. 2006; 24(6):1476-86. DOI: 10.1634/stemcells.2005-0299. View

Xu B, Chen H, Que Y, Xiao W, Zeng M, Zhang X . ALK interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma. Oncogene. 2019; 39(1):151-163. DOI: 10.1038/s41388-019-0973-5. View

Gregory B, Cheung V . Natural variation in the histone demethylase, KDM4C, influences expression levels of specific genes including those that affect cell growth. Genome Res. 2013; 24(1):52-63. PMC: 3875861. DOI: 10.1101/gr.156141.113. View

10.

Krubasik D, Iyer N, English W, Ahmed A, Vias M, Roskelley C . Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition. Br J Cancer. 2006; 94(9):1326-32. PMC: 2361417. DOI: 10.1038/sj.bjc.6603101. View

11.

Shao H, Cheng H, Cook R, Tweardy D . Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res. 2003; 63(14):3923-30. View

12.

Li J, Zhang Z, Wang L, Zhang Y . The oncogenic role of Wnt10a in colorectal cancer through activation of canonical Wnt/β-catenin signaling. Oncol Lett. 2019; 17(4):3657-3664. PMC: 6403505. DOI: 10.3892/ol.2019.10035. View

13.

Farace C, Pisano A, Grinan-Lison C, Solinas G, Jimenez G, Serra M . Deregulation of cancer-stem-cell-associated miRNAs in tissues and sera of colorectal cancer patients. Oncotarget. 2020; 11(2):116-130. PMC: 6968784. DOI: 10.18632/oncotarget.27411. View

14.

Liu Y, Deguchi Y, Tian R, Wei D, Wu L, Chen W . Pleiotropic Effects of PPARD Accelerate Colorectal Tumorigenesis, Progression, and Invasion. Cancer Res. 2019; 79(5):954-969. PMC: 6397663. DOI: 10.1158/0008-5472.CAN-18-1790. View

15.

Chan H, La Thangue N . p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci. 2001; 114(Pt 13):2363-73. DOI: 10.1242/jcs.114.13.2363. View

16.

Donizy P, Halon A, Surowiak P, Kaczorowski M, Kozyra C, Matkowski R . Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up. Oncol Lett. 2016; 12(3):1667-1674. PMC: 4998224. DOI: 10.3892/ol.2016.4890. View

17.

Amini S, Fathi F, Mobalegi J, Sofimajidpour H, Ghadimi T . The expressions of stem cell markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3, Dppa4, and Esrrb in bladder, colon, and prostate cancer, and certain cancer cell lines. Anat Cell Biol. 2014; 47(1):1-11. PMC: 3968261. DOI: 10.5115/acb.2014.47.1.1. View

18.

Yu J, Hsiung C, Hsu H, Bao B, Chen S, Hsu G . Genetic variation in the genome-wide predicted estrogen response element-related sequences is associated with breast cancer development. Breast Cancer Res. 2011; 13(1):R13. PMC: 3109581. DOI: 10.1186/bcr2821. View

19.

Walter B, Klare P, Strehle K, Aschenbeck J, Ludwig L, Dikopoulos N . Improving the quality and acceptance of colonoscopy preparation by reinforced patient education with short message service: results from a randomized, multicenter study (PERICLES-II). Gastrointest Endosc. 2018; 89(3):506-513.e4. DOI: 10.1016/j.gie.2018.08.014. View

20.

Dang D, Chen X, Feng J, Torbenson M, Dang L, Yang V . Overexpression of Krüppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene. 2003; 22(22):3424-30. PMC: 2275074. DOI: 10.1038/sj.onc.1206413. View